858 Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target novel therapeutic pathways in oncology and immunology, with a focus on a PARG inhibitor currently in early clinical trials. The company aims to provide effective treatment options for patients suffering from cancer and immune-related diseases.
Funding
$110.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers and immune-related diseases lack effective treatment options due to the complex and evolving nature of these conditions and the limited number of druggable targets. The development of new therapies requires innovative approaches to target previously unaddressed pathways.
Solution
858 Therapeutics is developing a portfolio of small molecule drugs designed to act on novel therapeutic targets within oncology and immunology. Their approach focuses on identifying and inhibiting key proteins and pathways that drive disease progression, offering the potential for more effective and targeted treatments. Their lead program is a PARG (Poly(ADP-ribose) glycohydrolase) inhibitor, currently in early clinical development, which aims to disrupt cancer cell survival and proliferation. By targeting novel mechanisms, 858 Therapeutics seeks to address unmet needs in cancer and immune-related diseases.
Target Audience
The primary target audience includes patients suffering from cancer and immune-related diseases, as well as the medical professionals who treat them.
Features
- Focus on small molecule drug development for oncology and immunology.
- Lead program targeting PARG, a novel oncology target, currently in Phase 1 clinical trials.
- Development of drugs acting on novel therapeutic targets.
- Aims to discover innovative and meaningful drugs for patients with cancer and immune diseases.